

**MODERN VIEWS ON THE DIAGNOSIS OF COAGULOPATHIES:
FACTOR II (PROTHROMBIN) DEFICIENCY**

Oydinova Bakhtigul

cadet of the Department of Clinical Laboratory

Diagnostics with the course of Clinical Laboratory Diagnostics of PGD

Umarova Tamila Abdufattoevna

assistant of the Department of Clinical Laboratory

Diagnostics with the course of Clinical Laboratory Diagnostics of PGD

Hamzayev Javlon Maxmud o'g'li

Doctor of the Samarkand branch of the Republican Scientific

Center for Emergency Medical Care Samarkand State

Medical University Samarkand, Uzbekistan

Coagulopathy is a group of disorders characterized by impaired normal blood clotting, which can lead to either excessive bleeding or thrombosis. In the human body, the process of blood clotting (hemostasis) ensures the cessation of bleeding after vascular injury. However, when hemostasis is impaired, various problems arise, such as excessive bleeding or, conversely, an increased tendency to form blood clots.

Keywords: *coagulopathy, clotting factors, thrombosis, bleeding, blood vessels, mechanism*

Coagulopathy can manifest as a tendency to bleed (e.g., hemophilia, thrombocytopenia) or as an increased tendency to form clots (thrombophilia). In both cases, there is a risk of complications that can lead to serious health consequences.

Rare bleeding disorders (RBDs) include monogenic coagulopathies caused by a deficiency of plasma proteins involved in hemostasis, excluding von Willebrand disease and hemophilia A or B. RBDs include hereditary deficiencies of fibrinogen, prothrombin, and clotting factors V, VII, X, XI, XII, and XIII. The development of RBDs is usually due to recessive inheritance of unique or rare nucleotide changes in the genes encoding coagulation factors or in proteins required for the post-translational modification of these factors. RBDs are most common in ethnic groups with a tradition of consanguineous marriages, which increases the likelihood of homozygous carriage of the defective gene [20,21].

Despite achieved advances, the clinical characteristics of most rare bleeding disorders (RBDs) remain insufficiently documented, and patient management principles have been developed based on results of open observational studies. Due to the rarity of this pathology worldwide, no randomized controlled clinical trials have been conducted [15,16,17,18,19].

Hereditary coagulation factor II (FII) deficiency – prothrombin deficiency – is an autosomal recessive disorder characterized by reduced prothrombin activity in plasma, caused by either quantitative defects (hypoprothrombinemia) or qualitative defects (dysprothrombinemia) in the FII protein structure. The prevalence of FII deficiency in most countries is approximately 1 patient per 2,000,000 population [10,11,12,13,12].

FII is a glycoprotein synthesized in the liver in the presence of vitamin K. Under the influence of activated factor X (FXa) in the initiating phase of the coagulation cascade and the prothrombinase complex (amplification phase), FII is converted into thrombin. Thrombin, in turn, activates other plasma coagulation proteins and platelets, ultimately leading to the formation of a fibrin clot. FII deficiency is caused by variations in the F2 gene, which encodes prothrombin. There is no direct correlation between F2 genotype and disease phenotype [6,7,8,9].

Clinical manifestations. The main manifestation of FII deficiency is bleeding, which can occur spontaneously or after trauma. Hemorrhagic syndrome most commonly presents as mucosal bleeding, soft tissue hematomas of various locations, hemarthroses, bleeding during and after surgical interventions, and severe menstrual bleeding. Less common are gastrointestinal bleeding, hematuria, obstetric bleeding, and bleeding from the umbilical stump. About 7% of patients experience central nervous system (CNS) hemorrhages.

In hypoprothrombinemia with FII activity $<10\%$, bleeding is usually more severe than in cases with FII activity $\geq 10\%$, where mild to moderate mucosal bleeding is most typical. Dysprothrombinemia is characterized by a weak correlation between clinical and laboratory phenotypes. Heterozygous carriers of FII deficiency generally have FII activity within 40–75% and are mostly asymptomatic [1,2,3,4,5].

Laboratory diagnosis. Coagulological examination is conducted in stages:

Stage 1. Coagulological screening for suspected hemorrhagic conditions includes:

- Activated partial thromboplastin time (aPTT)
- Prothrombin time (PT)
- Thrombin time (TT)
- Fibrinogen concentration (Clauss method)
- Bleeding time (standardized methods, e.g., Ivy method)
- Instrumental assessment of platelet function

These tests allow determination of the type of coagulation disorder. FII deficiency is characterized by prolonged aPTT and PT, while other above-mentioned parameters remain within normal ranges.

Stage 2. This stage is performed to verify the presence of FII deficiency when prolonged aPTT and PT are detected. A one-stage method for determining FII activity is used, based on calculating the relationship between PT and the percentage content of prothrombin complex factors, constructed using various dilutions of control plasma.

Stage 3. If decreased FII activity is identified, an enzyme immunoassay (ELISA) for FII antigen can be performed to verify hypo- or dysprothrombinemia. Methods using various snake venoms (e.g., *Echis carinatus*, Taipan, and tetrarin) allow differentiation of certain variants of dysprothrombinemia.

It is important to note the possibility of acquired FII deficiency in the context of lupus anticoagulant-associated hypoprothrombinemic syndrome, which differs from hereditary FII deficiency in terms of clinical course and the presence of antiphospholipid antibodies [20,21,22,23,24].

References:

1. Abduhakimov B. A. et al. Bolalar va o'smirlarda birlamchi tuberkulyozning o'ziga xos kechish xususiyatlari va klinik-laboratoriya usullari //Ta'lim innovatsiyasi va integratsiyasi. – 2024. – T. 32. – №. 3. – С. 139-143.
2. Бердиярова Ш. Ш. и др. Клинико-лабораторная диагностика фолиевой кислотодефицитной анемии //TADQIQOTLAR. UZ. – 2024. – Т. 49. – №. 3. – С. 46-53.
3. Umarova T. A., Kudratova Z. E., Axmadova P. Role of conditionally pathogenic microflora in human life activities //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 11. – С. 29-32.
4. Muhamadiyeva L. A., Kudratova Z. E., Sirojeddinova S. Pastki nafas yo'llari patologiyasining rivojlanishida atipik mikrofloraning roli va zamonaviy diagnostikasi //Tadqiqotlar. Uz. – 2024. – Т. 37. – №. 3. – С. 135-139.
5. Umarova T. A., Kudratova Z. E., Norboyeva F. Modern aspects of etiology and epidemiology of giardias //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 11. – С. 25-28.
6. Isomadinova L. K., Daminov F. A. Glomerulonefrit kasalligida sitokinlar ahamiyati //Journal of new century innovations. – 2024. – Т. 49. – №. 2. – С. 117-120.
7. Umarova T. A., Kudratova Z. E., Maxmudova H. Mechanisms of infection by echinococcosis //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 11. – С. 18-21.
8. ДАМИНОВ Ф. А., ИСОМАДИНОВА Л. К., РАШИДОВ А. Этиопатогенетические и клинико-лабораторные особенности сальмонеллеоза //TADQIQOTLAR. UZ. – 2024. – Т. 49. – №. 3. – С. 61-67.
9. Umarova T. A., Kudratova Z. E., Vaxromova M. Autoimmune diseases: new solutions in modern laboratory diagnostics //International Conference on Modern Science and Scientific Studies. – 2024. – С. 78-81.
10. Бердиярова Ш. Ш. и др. Узловой зоб и его клинико-лабораторная диагностика //TADQIQOTLAR. UZ. – 2024. – Т. 49. – №. 3. – С. 38-45.
11. Umarova T. A., Kudratova Z. E., Muhsinovna R. M. The main purpose of laboratory diagnosis in rheumatic diseases //International Conference on Modern Science and Scientific Studies. – 2024. – С. 82-85.
12. Umarova T. A., Kudratova Z. E., Ruxshona X. Contemporary concepts of chronic pancryatitis //International Conference on Modern Science and Scientific Studies. – 2024. – С. 11-15.

13. Хамидов З. З., Амонова Г. У., Исаев Х. Ж. Некоторые аспекты патоморфологии неспецифических язвенных колитов //Молодежь и медицинская наука в XXI веке. – 2019. – С. 76-76.
14. Umarova T. A., Kudratova Z. E., Muminova G. Instrumental diagnostic studies in chronic pancreatitis //International Conference on Modern Science and Scientific Studies. – 2024. – С. 16-20.
15. Атамурадовна М.Л., Рустамовна Р.Г., Эркиновна К.З. Роль современных биомаркеров в изучении различных поражений головного мозга //Достижения науки и образования. – 2020. – №. 10 (64). – С. 88-90.
16. Рустамова Г. Р., Мухамадиева Л. А. Современные аспекты клинико-лабораторных методов исследования острой ревматической лихорадки //International scientific review. – 2020. – №. LXVI. – С. 106-110.
17. Кудратова З.Е. и др. Роль цитокиновой регуляции при обструктивном синдроме атипичного генеза у детей // Анналы Румынского общества клеточной биологии. – 2021. – Т. 25. – №. 1. – С. 6279-6291.
18. Erkinovna K. Z. et al. Bronchial obstruction syndrome in young children with respiratory infections of different etiology: features of clinical manifestations and immune response //Проблемы науки. – 2021. – №. 1 (60). – С. 60-62.
19. Кудратова З.Е. и др. Хламидийные инфекции (внутриклеточная инфекция) в развитии бронхита // TJE-Tematics journal of Education ISSN. – 2021. – С. 2249-9822.
20. Kudratova Z. E. et al. Principles of therapy of chlamydial and mycoplasma infections at the present stage //Вопросы науки и образования. – 2021. – №. 28 (153). – С. 23-26.
21. Rustamova G. R., Kudratova Z. E. CHRONIC ENDOMETRITIS OLD ISSUES NEW POSSIBILITIES //Western European Journal of Medicine and Medical Science. – 2024. – Т. 2. – №. 5. – С. 12-14.
22. Erkinovna K. Z., Rustamovna R. G., Suratovna H. F. LABORATORY MARKERS OF PERINATAL HYPOXIC DAMAGE TO THE CENTRAL NERVOUS SYSTEM IN NEWBORNS //Наука, техника и образование. – 2020. – №. 10 (74). – С. 102-104.
23. Mukhamadieva L. A., Rustamova G. R., Kudratova Z. E. IMMEDIATE RESULTS OF COMPLEX TREATMENT OF CHILDREN WITH CHRONIC TONSILLITIS AND CHRONIC ADENOIDITIS ASSOCIATED WITH CMV AND EBV //Western European Journal of Medicine and Medical Science. – 2024. – Т. 2. – №. 5. – С. 20-24.
24. Umarova T. A., Kudratova Z. E., Norxujayeva A. Etiopathogenesis and modern laboratory diagnosis of prostatitis //International Conference on Modern Science and Scientific Studies. – 2024. – С. 6-10.